Emergent BioSolutions (EBS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $3.67, $0.48 better than the analyst estimate of $3.19. Revenue for the quarter came in at $583 million versus the consensus estimate of $563.94 million.

“Emergent’s financial and operational performance in 2020 reflects the impact we are making in addressing the growing public health threat landscape and meeting our mission to protect and enhance the lives of patients,” said Robert G. Kramer, president and CEO of Emergent BioSolutions. “We look forward to continuing to execute on our strategy with vaccines, therapeutics, devices, and contract development and manufacturing services. Our strong core business, robust development pipeline, and innovator and public-private partnership opportunities position us to remain leaders in the market and create long-term shareholder value.”

GUIDANCE:

Emergent BioSolutions sees FY2021 revenue of $1.95-2.05 billion, versus the consensus of $1.93 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• SAP SE (SAP) saw a sharp acceleration in new cloud business across its cloud portfolio
• Atlassian (TEAM) Prelim. Q3 Revenue Beats Consensus
• Simulations Plus (SLP) Tops Q2 EPS by 1c, Revenues Beat